©2014 Baishideng Publishing Group Inc.
World J Methodol. Jun 26, 2014; 4(2): 73-90
Published online Jun 26, 2014. doi: 10.5662/wjm.v4.i2.73
Published online Jun 26, 2014. doi: 10.5662/wjm.v4.i2.73
Table 4 Monoclonal antibodies evaluated in multiple myeloma therapy[147]
| Monoclonal antibodies targeting tumor cells specific antigens | |
| Antigen | MoAb |
| CD20 | Rituximab, Tositumomab, 20-C2-2b Veltuzumab |
| CS1 | Elotuzumab |
| CD138 | B-B4, BC/B-B4, DL-101, 1D4, 1.BB.210, MI15, 2Q1484, 5F7, 104-9, 281-2, nBT062-SMCL-DM1, BT062-SPDM4, nBT062-SPP-DM1 |
| CD38 | Doratumumab, MOR202 |
| CD40 | Lucatuzumab, Lorvotuzumab |
| IGF-1 | AVE1642, AMG479 IMCA12, R15507, Figitumumab, Dalotuzumab |
| CD317 | AHM, Defucosylated AHM, XmAb 5592 |
| CD48 | Anti-CD48 MoAb |
| b2 m | IgG anti-b2m, IgM anti-b2m |
| CD70 | SGN-70 |
| CD74 | Milatuzumab |
| HLADR | ID09C3, 2D7-DB |
| CD229 | Anti-CD229 |
| GM2 ganglioside | BIW-8962 |
| ICAM-1 | BI-505 |
| Ku | 5E2 |
| Monoclonal antibodies targeting components of bone marrow microenvironment and plasma cellr–bone marrow stromalcell interaction | |
| IL-6 | Siltuximab, Tocilizumab, NRI, Elsilimomab, Azintrel, SANT-7 |
| VEGF | Bevacizumab |
| EGFR | Cetuximab |
| FGFR-3 | MFGR1877A |
| RANKL | Denosumab |
| Dickkopf | Anti-DKK1, BrlQ880 |
| Activin | RAP-011, ACE-011 |
| BAFF | Atacicept, SG1 |
| Other potential targets | |
| TRAIL-R1 | Mapatuzumab |
| TRAIL-R2 | Lexatuzumab |
| PD-L1 | CD-011 |
| VLA-4 | Natalizumab |
| Kininogen | C11C1 |
- Citation: Ria R, Reale A, Vacca A. Novel agents and new therapeutic approaches for treatment of multiple myeloma. World J Methodol 2014; 4(2): 73-90
- URL: https://www.wjgnet.com/2222-0682/full/v4/i2/73.htm
- DOI: https://dx.doi.org/10.5662/wjm.v4.i2.73